Clinical Trial 23393

• Overview

  Study Title:

  A Phase 2, Open-Label Study of PCS6422 with Capecitabine in Patients with Advanced or Metastatic Breast Cancer

  Summary:

  This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors.

  Objective:

  Primary Objectives: * To assess the antitumor activity of PCS6422 administered with Cap in patients with advanced or metastatic breast cancer * To assess the safety and tolerability of PCS6422 administered with Cap in patients with advanced or metastatic breast cancer * To determine the dosage regimens of PCS6422 administered with Cap in patients with advanced or metastatic breast cancer for use in a pivotal study *To further characterize and evaluate the exposure-AE relationships of PCS6422 with Cap *To further characterize and evaluate the exposure-efficacy relationships of PCS6422 with Cap Secondary Objectives: *To further assess the antitumor activity of PCS6422 administered with Cap in patients with advanced or metastatic breast cancer * To assess survival benefits of PCS6422 administered with Cap * To evaluate the incidence of adverse events of special interest (AESIs) * To characterize the effect of PCS6422 on DPD activity during Cap dosing and the pharmacokinetic (PK) profiles of Cap, 5-FU, and the quantifiable main metabolite (FBAL) * To characterize the PK of PCS6422

• Treatments

  Therapies:

  Chemotherapy (NOS); Therapy (NOS)

  Medications:

  PCS6422 (); Xeloda (capecitabine); capecitabine ()

• Inclusion Criteria

  Inclusion Criteria:
  • Age 18 years or older at Screening
  • Diagnosis of histologically confirmed breast cancer that is unresectable. The following subsets of breast cancer are included:
  • Patients with triple-negative breast cancer, advanced or metastatic
  • Patients with hormone receptor (HR) positive, ER positive, HER2 negative advanced or metastatic breast cancer
  • Measurable disease in accordance with RECIST 1.1 obtained by imaging within 28 days prior to C1D1
  • Other therapies are not indicated (eg, resistant or intolerant to taxanes and/or an anthracycline-containing regimen) for treatment of advanced or metastatic breast cancer
  • Life expectance of at least 24 weeks
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 at screening
  • Has adequate bone marrow, liver, and renal function as assessed by laboratory requirements conducted within 7 days before C1D1 (Note: labs will also be repeated pre-dose on C1D1 to confirm eligibility).
  • Other criteria apply

• Exclusion Criteria

  Exclusion Criteria:
  • Received any line of treatment for advanced or metastatic breast cancer within 21 days or 5 half-lives (whichever is longer) prior to randomization
  • Currently receiving any hormone replacement therapy, unless discontinued within 21 days prior to randomization
  • Received IV 5-FU or oral 5-FU analog in the 4 weeks prior to C1D1
  • Received DPD inhibitor within 4 weeks prior to C1D1
  • Has homozygous or compound heterozygous DPYD variants that result in complete or near-complete absence of DPD activity Cardiac exclusions:
  • Has history or presence of clinically significant abnormal 12-lead electrocardiogram (ECG) results, in the Medical Monitor or Investigator's opinion
  • Has prolonged QTc (with Fridericia's correction) of >480 msec performed at Screening
  • Has a history of prolonged QTc interval, ventricular tachycardia/fibrillation or significant ventricular arrhythmia, or Torsades de Pointes, or a history of ventricular ablation for arrhythmia
  • Has congenital long QT syndrome or a family history of long QT syndrome
  • Has other clinically significant cardiac disease including, but not limited to, myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery 12 or less months prior to randomization, congestive heart failure
  • Class II per the New York Heart Association, or history of myocarditis
  • Is pregnant or breastfeeding

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.